Biosimilars: Are they bioequivalent?

Digestive Diseases

Volumn 32, Issue , 2014, Pages 82-87

  Gomollón, Fernando ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Biologics; Biosimilars; Regulatory authorities

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; GENERIC DRUG; INFLIXIMAB; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTICLE; BIOEQUIVALENCE; CANADIAN; CLINICAL TRIAL; CROHN DISEASE; DRUG INDICATION; DRUG SURVEILLANCE PROGRAM; FUCOSYLATION; GLYCOSYLATION; HUMAN; INFLAMMATORY BOWEL DISEASE; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS; ANIMAL; INFLAMMATORY BOWEL DISEASES; NOMENCLATURE; THERAPEUTIC EQUIVALENCE;

ANIMALS; BIOSIMILAR PHARMACEUTICALS; HUMANS; INFLAMMATORY BOWEL DISEASES; TERMINOLOGY AS TOPIC; THERAPEUTIC EQUIVALENCY;

EID: 84919784510     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000367833     Document Type: Article

References (26)

1. Plitnick LM, Herzyk DJ: Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Waltham, Academic Press, 2013.
2. D'Haens GR, Sartor RB, Silverberg MS, Petersson J, Rutgeerts P: Future directions in inflammatory bowel disease management. J Crohns Colitis 2014; 8: 726-734.
3. Gecse KB, Khanna R, van den Brink GR, Ponsioen CY, Lowenberg M, Jairath V, et al: Biosimilars in IBD: hope or expectation? Gut 2013; 62: 803-807.
4. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, et al: Biosimilars - why terminology matters. Nat Biotechnol 2011; 29: 690-693.
5. Chan AC, Carter PJ: Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10: 301-316.
6. Ebbers HC: Biosimilars: in support of extrapolation of indications. J Crohns Colitis 2014; 8: 431-435.
7. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB: Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov 2012; 11: 527-540.
8. Warren JB: Generics, chemisimilars and biosimilars: is clinical testing fit for purpose? Br J Clin Pharmacol 2013; 75: 7-14.
9. Hlavaty T, Letkovsky J: Biosimilars in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2014; 26: 581-587.
10. Rinaudo-Gaujous M, Paul S, Tedesco ED, Genin C, Roblin X, Peyrin-Biroulet L: Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther 2013; 38: 914-924.
11. Mendes de Abreu M, Strand V, Levy RA, Araujo DV: Putting the value into biosimilar decision making: the judgment value criteria. Autoimmun Rev 2014; 13: 678-684.
12. Blackstone EA, Fuhr JP Jr: Innovation and competition: will biosimilars succeed? The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety. Biotechnol Healthc 2012; 9: 24-27.
13. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al: A randomised, double- blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72: 1605-1612.
14. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al: A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72: 1613-1620.
15. Fiorino G, Girolomoni G, Lapadula G, Orlando A, Danese S, Olivieri I, et al: The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev 2014; 13: 751-755.
16. Danese S, Gomollon F, Michetti P: EMA response to ECCO position statement on biosimilars. J Crohns Colitis 2014; 8: 259.
17. Lee H: Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J 2014; 16: 22-26.
18. Ordas I, Mould DR, Feagan BG, Sandborn WJ: Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics- based dosing paradigms. Clin Pharmacol Ther 2012; 91: 635-646.
19. Calvo B, Zuniga L: EU's new pharmacovigilance legislation: considerations for biosimilars. Drug Saf 2014; 37: 9-18.
20. Hoentjen F, Haarhuis BJ, Drenth JP, de Jong DJ: Elective switching from infliximab to adalimumab in stable Crohn's disease. Inflamm Bowel Dis 2013; 19: 761-766.
21. Ebbers HC, Crow SA, Vulto AG, Schellekens H: Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 2012; 30: 1186-1190.
22. Dorner T, Strand V, Castaneda-Hernandez G, Ferraccioli G, Isaacs JD, Kvien TK, et al: The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013; 72: 322-328.
23. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, et al: Biosimilars: what clinicians should know. Blood 2012; 120: 5111-5117.
24. Beck A, Wurch T, Bailly C, Corvaia N: Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10: 345-352.
25. Wang P, Dong S, Shieh JH, Peguero E, Hendrickson R, Moore MA, et al: Erythropoietin derived by chemical synthesis. Science 2013; 342: 1357-1360.
26. Hsieh-Wilson LC, Griffin ME: Chemistry. Improving biologic drugs via total chemical synthesis. Science 2013; 342: 1332-1333.